Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6231314 | 1.00 | TACR1 (0.81) | TACR1 | |
| Hydrochloric Acid SCHEMBL7052869 | 0.98 | TACR1 (0.78) | TACR1 | |
| Hydrochloric Acid SCHEMBL7052874 | 0.98 | TACR1 (0.78) | TACR1 | |
| SCHEMBL6232825 | 0.92 | TACR1 (0.77) | TACR1 | |
| SCHEMBL6231286 | 0.92 | TACR1 (0.77) | TACR1 | |
| SCHEMBL6556017 | 0.90 | TACR1 (0.87) | TACR1 | |
| Hydrochloric Acid SCHEMBL7712941 | 0.90 | TACR1 (0.74) | TACR1 | |
| Hydrochloric Acid SCHEMBL7712939 | 0.90 | TACR1 (0.74) | TACR1 | |
| SCHEMBL8090256 | 0.89 | TACR1 (1.00) | TACR1 | |
| Hydrochloric Acid SCHEMBL8541427 | 0.89 | TACR1 (0.85) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010023248-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | HOWARD HARRY R (US) | 2001-09-20 | — | — | US | claimed |
| EP-0675886-B1 | AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2000-07-05 | — | — | EP | claimed |
| US-5854262-A | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | PFIZER INC. (US) | 1998-12-29 | — | — | US | claimed |
| WO-1994013663-A1 | AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1994-06-23 | — | — | WO | claimed |
| EP-1517708-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1515708-A1 | COMBINATIONS OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION | Pfizer Products Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040220274-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| US-20040001895-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-01 | — | — | US | disclosed |
| WO-2004000355-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003105815-A1 | COMBINATION OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION | PFIZER PRODUCTS INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030162766-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| US-20010023248-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | HOWARD HARRY R (US) | 2001-09-20 | — | — | US | disclosed |
| EP-1099446-A2 | Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1095655-A2 | NK-1 receptor antagonists and eletriptan for the treatment of migraine | Pfizer Products Inc. (US) | 2001-05-02 | — | — | EP | disclosed |
| EP-0675886-B1 | AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5854262-A | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | PFIZER INC. (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0806423-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists | PFIZER INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1994013663-A1 | AMINOMETHYLENE SUBSTITUTED NON-AROMATIC HETEROCYCLES AND USE AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006135-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, HTR3A | TACR1 1/4885 |
| US-20010023248-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | NPY1R, OPRK1, OPRL1 | TACR1 5/4885 |
| US-20030162766-A1 | Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists | NPY1R, OPRK1, TACR1 | TACR1 3/4885 |
| US-20040001895-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, ADORA1 | TACR1 1/4885 |
| US-20040220274-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, ADORA1 | TACR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.